Navigation Links
XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Date:11/17/2011

f blepharospasm, in 21 countries for the treatment of cervical dystonia (spasmodic torticollis), and in 17 countries for post-stroke spasticity of the upper limb (XEOMIN® is not approved for the treatment of spasticity in the U.S.). Due to unit differences in the LD50 assay, XEOMIN® units are specific to XEOMIN®. Therefore unit doses recommended for XEOMIN® are not interchangeable with those for other preparations of Botulinum toxin. Comparative clinical study results suggest that XEOMIN® and the comparator product containing conventional Botulinum toxin type A complex (900 kD) are of equal potency when used with a dosing conversion ratio of 1:1.

XEOMIN® is the only botulinum toxin product that does not require refrigeration during transport or storage.

XEOMIN® is available in 50 and 100 unit vials. The 50 unit vial helps facilitate flexible dosing and offers reduced product wastage as well as cost savings.

Merz Pharmaceuticals GmbH (www.merz.com):

Merz Pharmaceuticals, a member of the Merz Pharma Group of companies, is an innovative and international specialty healthcare company specializing in the research, development and marketing of pharmaceuticals for the treatment of neurological and psychiatric diseases. In addition to developing XEOMIN®, the company has developed memantine (Namenda®, Memary®, Axura®, Ebixa®) - the first drug for the treatment of moderate to severe Alzheimer's disease, which is marketed by Forest in the US, Daiichi-Sankyo in Japan, and Merz/Lundbeck in Europe and rest of the world. The company also focuses on the development of innovative therapies within the therapeutic areas of hepatology, metabolic diseases and dermatology.

XEOMIN® is a registered trademark of Merz Pharma GmbH & Co KGaA.


'/>"/>
SOURCE Merz Pharmaceuticals GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
2. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
3. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
6. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
7. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
8. New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
9. Abbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011
10. Positive Results from Phase 2 Trial of Mesoblasts Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
11. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Cynosure, Inc. (Nasdaq: CYNO ), which ... procedures and precision surgical applications worldwide, today reported ... 30, 2015. "Our North American business ... increased 47 percent year-over-year and selling prices remained ... "While our international results reflected the economic slowdowns ...
(Date:7/28/2015)... Baebies, Inc. today announced the completion of ... oversubscribed round of financing included key investors Rex Health ... Capital, Triad, LLC, the Duke Angel Network and a ... Advanced Liquid Logic,s (ALL) former investors including Charleston Angel ... "Rex is pleased to support this promising young ...
(Date:7/28/2015)... 28, 2015  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today its results ... 2015.  Pat Mackin, Chairman, President and ... to execute on our growth strategy with solid progress ... we announced plans to transition to a direct sales ...
Breaking Medicine Technology:Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 2Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 3Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 4Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 5Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 6Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 7Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 8Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 9Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 10Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 11Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 12Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year 13Baebies, Inc. Raises $13 Million in Oversubscribed Round of Financing 2CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14
... , , , PARSIPPANY, N.J., Jan. 11 ... pharmaceutical industry your survival depends on not only what you ... Pharma market research is key. Whoever has the right ... U.S. pharmaceutical industry is the largest (and growing) market in ...
... , ... Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP ... clinical trial of a prototype formulation of its proprietary delayed-release cysteamine ... M.D., Professor of Pediatrics at the University of California, San Diego, ...
Cached Medicine Technology:Elite Pharma Insiders to Reveal Key Survival Strategies for Pharmaceutical Industry in 2010 2Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 2Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 3Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 4Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 5Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 6Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis 7
(Date:7/29/2015)... ... July 29, 2015 , ... Zofran ... Judicial Panel on Multidistrict Litigation (JPML), according to court documents.* Attorneys handling ... website, the Zofran Birth Defects Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate ...
(Date:7/29/2015)... ... July 29, 2015 , ... The New Foundation AZ recently started ... end will cost the 501(c) organization nearly $1 million, will both update the facilities’ ... “We took it down to the studs,” said Geraldine Leary, the New Foundation AZ ...
(Date:7/29/2015)... ... 2015 , ... The Woodlands and Spring Fit Body Boot Camps have implemented ... causes each month. The new system will track each time a client uses social ... each facility, the boot camps will donate 20 cents to a selected charity. , ...
(Date:7/29/2015)... MN (PRWEB) , ... July 29, 2015 , ... ... announces that it has entered into a partnership with 247Ergo, an ergonomics specialty ... health and wellness. Ergonomics projects that the companies undertake could improve worker mobility, ...
(Date:7/29/2015)... ... July 29, 2015 , ... Indiana is known for basketball, ... the home of Zerorez Indianapolis, which plans to expand across the state. , Ray ... our second full year in business and we should double our first year’s revenue. ...
Breaking Medicine News(10 mins):Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 2Health News:HealthPostures and 247Ergo Partnership Strengthens America's Wellness 3Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 2Health News:Zerorez® Announces Plans to Roll Across Indiana—“The Crossroads of America.” 3
... Revenue Tops $45 Million Reflecting 79% Growth Over Prior ... Revises 2007 Guidance and Reaffirms 2008 Guidance, COEUR ... NHWK ), the leading provider of radiology,solutions to ... for its third quarter ended September 30, 2007. Revenue,grew ...
... ROCKVILLE, Md., Oct. 30 Vanda Pharmaceuticals,Inc. (Nasdaq: ... the development,and commercialization of clinical-stage product candidates for ... the,Company,s Proof- of-Concept Phase II clinical trial evaluating ... This Phase II study examined the effects of ...
... YORK, Oct. 30 Florida already allows it. And ... pharmacists the,authority to independently prescribe prescription drugs, a move ... billion in 2006 to,$145 billion by 2012, according to ... Kalorama Information. The study shows that 77% of ...
... On Sunday, November 4,2007, Eli Lilly and Company ... with,the investment community and media to review the details ... Association,Scientific Sessions in Orlando, Florida. This call will follow ... TRITON TIMI-38 trial. The Lilly conference call will ...
... called retinoic acid was associated with reduced lung cell growth ... study published online October 30 in the Journal of ... at elevated risk for lung cancer. According to one hypothesis, ... continue to grow and evolve into cancer even after that ...
... Oct. 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... and,medical device company, is scheduled to participate in ... held November 5 - 7 in New York ... will make a 30-minute,presentation followed by a 30-minute ...
Cached Medicine News:Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 2Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 3Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 4Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 5Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 6Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 7Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 8Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 9Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 10Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 11Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 12Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 13Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 14Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 15Health News:NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results 16Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 2Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 3Health News:Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties 4Health News:By 2012, Prescribing Pharmacists Could Influence $145 Billion in Drug Sales 2Health News:Vitamin A derivative associated with reduced growth in some lung cells 2
... disposable template is designed for ... eliminate the need for cleaning. ... premium silicone molded over a ... needle placement while maintaining needle ...
A sterile, cost-effective solution to eliminating the risk of cross-contamination....
... Reusable Template is designed for use ... system for prostate brachytherapy. Please be ... software match the graphics on the ... pins protruding from lower surface which ...
... latest introduction in the family of positioners ... of the stepping platform features a top-loading ... The EXII steeping unit has a digital ... display of transducer position and a serial ...
Medicine Products: